Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Satellos Bioscience Inc > Strong volume, high close @.25 cents
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(13)
•••
Post by DrHolidayon Jul 12, 2018 4:39pm
150 Views
Post# 28308779

Strong volume, high close @.25 cents

Strong volume, high close @.25 centsSpecial Note:  
Total Dollar Volume = $5,708,000.00

If you sold your stock today, thinkin you'll be able to buy back, then think again because the high close accompanied by the strong volume bodes well and we haven't even received the news yet which is soon to be released as promised. Management is just dotting the i's and crossing the t's before it gets the ok from the legal department at ICO.
Gonna shoot some more of them dang injuns who tried to scalp us.
They got scalped when they lost their stock by selling out too cheap. Sellers remorse, and they will be bouncing off the walls of the loony bin when they find out how much money they left lying on the table. Let the seller beware. DOC.

https://www.stockwatch.com/Quote/Detail.aspx?symbol=ICO&region=C
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities